ENTRADA THERAPEUTICS

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

08 أغسطس 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

01 أغسطس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

06 يونيو 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics Reports First Quarter 2023 Financial Results

10 مايو 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

04 أبريل 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

29 مارس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

06 مارس 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

27 فبراير 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)

09 فبراير 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable

09 يناير 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

19 ديسمبر 2022 16:30:00 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

22 نوفمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

07 نوفمبر 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

30 أغسطس 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

11 أغسطس 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1

04 أغسطس 2022 07:00:03 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

19 يوليو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

06 يوليو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

01 يونيو 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Entrada Therapeutics Reports First Quarter 2022 Financial Results

12 مايو 2022 07:00:01 بحسب Nasdaq GlobeNewswire